Women's Health · LP-104
Levonorgestrel Tablets
Generic medicine development record. Review the proposed presentation and the professional reference information below.
Development record
- Portfolio reference
- LP-104Women's Health
- Generic identity
- LevonorgestrelTablet
- Registration
- Not establishedProduct-specific evidence required
- Availability
- Not marketedNo offer of supply
01 · Ingredient reference
Record identity and reference background.
- Portfolio reference
- LP-104
- Generic ingredient
- Levonorgestrel
- Dosage form
- Tablet
- Proposed strength
- 1.5 mg single tablet; 750 mcg x 2 tablets
- Proposed pack
- Blister; emergency pack
- Portfolio category
- Women's Health
About Levonorgestrel
Levonorgestrel is a progestin used in different contraceptive products. This catalogue record combines emergency-contraception tablets with a much lower-strength daily progestin-only presentation. These have different purposes and instructions and must be clearly distinguished. General ingredient information cannot establish how an individual pack should be used, and a person seeking emergency contraception should obtain timely advice from an appropriate healthcare service.
How to read this profile
Scientific information relates to the ingredient and dosage-form context. It is not approved Luang Pharma labelling, a clinical recommendation, or evidence of equivalence to a referenced product. Multiple strengths or presentations represent separate proposed variants and must not be treated as interchangeable.
02 · Professional background
Scientific & clinical reference
Read the clinical context, selected safety considerations and presentation-specific information below.
Clinical context and therapeutic role
Emergency levonorgestrel contraception is intended for a defined episode after unprotected intercourse or contraceptive failure. It does not end an established pregnancy. A low-strength daily progestin-only pill is a separate ongoing contraceptive method. Neither protects against sexually transmitted infections. Suitability, interactions, pregnancy assessment, follow-up and locally available alternatives require professional review. The linked emergency-contraception monograph must not be applied to the daily presentation.
Important safety considerations
Nausea, headache, abdominal discomfort, fatigue and changes in bleeding can occur. A delayed period or suspected pregnancy requires appropriate testing and review. Severe lower abdominal pain needs medical assessment, including consideration of ectopic pregnancy. Enzyme-inducing medicines can reduce contraceptive effectiveness. Because the record covers distinct presentations, product-specific contraindications and instructions must be checked rather than combining them into a single regimen.
These are selected considerations, not a complete list. Use the current instructions or approved label for the exact authorised product and seek appropriate professional advice.
Presentation, handling and storage
Emergency packs and daily cycle packs should have separate verified specifications and clear presentation labels. The listed 1.5 mg, 750 mcg and 30 mcg values are not interchangeable, and the catalogue must not imply that their packs share a dosing schedule.
Keep the medicine in the labelled original pack with its leaflet. Check the expiry date and pack integrity before dispensing. The authorized label must determine storage temperature, protection from moisture or light, and disposal; no shelf life or in-use period can be established from a catalogue entry.
Final composition, instructions, shelf life and storage conditions are not established by this portfolio entry. They must come from the controlled documentation for the specific product.
Points for professional review
First identify the exact presentation and purpose. Review timing-sensitive needs, interacting medicines, pregnancy possibility and follow-up, using current locally authorized contraceptive information.
03 · Product enquiry
Documentation & regulatory status
Evidence status
What is established — and what remains open
This record has received an editorial evidence-layer review. The review separates catalogue facts from unresolved product-specific fields and external context; it is not medical, regulatory or market-authorisation approval.
Layer 01
Controlled catalogue facts
- Generic ingredient
- Levonorgestrel
- Dosage form / presentation
- Tablet
- Catalogue strength
- 1.5 mg single tablet; 750 mcg x 2 tablets
- Catalogue pack
- Blister; emergency pack
- Portfolio category
- Women's Health
Layer 02
Unresolved product-specific fields
- Mixed emergency and ongoing daily contraception in one record. Split into separate presentation-level records before regulated product promotion or supply.
- P015 — A single record expressly combines emergency and cycle packs, with 1.5 mg, 750 mcg x 2 and 30 mcg entries.
- Exact release/coating/scoring characteristics and formulation-specific administration instructions require controlled product documentation where applicable.
- Approved indication, patient eligibility and dosing are not established by this portfolio record.
- Registration, manufacturing/site status, supply availability, storage conditions and shelf life remain product- and market-specific evidence items.
Layer 03
Attributed external context
- MedlinePlus: Levonorgestrel — ingredient/formulation referencegovernment-hosted medicine monograph
- NHS: progestogen-only pillgovernment or public health guidance
These references provide scientific or regulatory context only. They are not Luang Pharma product labelling, registration, manufacturing evidence, equivalence evidence or confirmation of supply.
Layer 04
Documents required to close the record
- Separate presentation records for emergency-contraception and daily progestin-only products, with strength-to-pack mapping and market-specific labels.
- Controlled product master/specification confirming the exact ingredient identity, dosage form, strength variant and pack mapping.
- Destination-market authorisation or other lawful supply-route evidence plus the approved label/leaflet/IFU, where applicable.
- Product-specific composition/excipient, storage, shelf-life and pack-control documentation.
- Manufacturing-site and supply-status evidence before any public claim of installed capability, registration, availability or equivalence.
For LP-104, identify the destination country, intended professional use, proposed presentation and the role of your organisation. The appropriate supply route and available documentation must be confirmed for that case.
- Confirm the legal entity, manufacturing site and authorised scope for the proposed supply chain.
- Confirm product registration or another lawful route, approved labelling and the applicable destination requirements.
- Request relevant product information, specifications and supporting evidence through the company contact.
- Confirm storage, transport, traceability, complaints and safety-reporting responsibilities before any agreement.
The public catalogue extends beyond the initial planned facility modules. A listing does not mean that the dosage form is installed, qualified or licensed at Boten.
04 · External sources
Sources and further reading
External sources are provided for reference. Their authors do not endorse Luang Pharma, and another product’s authorisation does not transfer to this portfolio record. Source availability and wording can change.
Professional enquiries
Request product-specific evidence for LP-104.
State the exact presentation, organisation, destination and evidence needed. This public record is not an offer of supply.